Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution

[1]Hortobagyi GN, de la Garza SJ, Pritchard K, et al: The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005, 6:391-401.HortobagyiGNde la GarzaSJPritchardKet alThe global breast cancer burden: variations in epidemiology and survivalClin Breast Cancer2005639140110.3816/CBC.2005.n.043Search in Google Scholar

[2]Albain KS, de la Garza SJ, Pienkowski T, et al: Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer 2005, 6:412-420.AlbainKSde la GarzaSJPienkowskiTet alReducing the global breast cancer burden: the importance of patterns of care researchClin Breast Cancer2005641242010.3816/CBC.2005.n.045Search in Google Scholar

[3]Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987SlamonDJClarkGMWongSGet alHuman breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience235177182198710.1126/science.3798106Search in Google Scholar

[4]Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712,1999SlamonDJGodolphinWJonesLAet alStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience244707712199910.1126/science.2470152Search in Google Scholar

[5]Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.ForceTKrauseDSVan EttenRAMolecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionNat Rev Cancer2007733234410.1038/nrc2106Search in Google Scholar

[6]Perez EA, Romond EH, Suman VJ, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/ without trastuzumab in patients with HER2- positive breast cancer. J Clin Oncol 25:6s, 2007 (suppl 18S; abstr 512)PerezEARomondEHSumanVJet alUpdated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/ without trastuzumab in patients with HER2- positive breast cancerJ Clin Oncol256s2007(suppl 18S; abstr 512)10.1200/jco.2007.25.18_suppl.512Search in Google Scholar

[7]Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005RomondEHPerezEABryantJet alTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med35316731684200510.1056/NEJMoa052122Search in Google Scholar

[8]Slamon DJ, Eiermann W, Robert NJ, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: BCIRG006 study. Cancer Res 69:500s, 2009 (abstr 62)SlamonDJEiermannWRobertNJet alPhase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: BCIRG006 studyCancer Res69500s2009(abstr 62)10.1158/0008-5472.SABCS-09-62Search in Google Scholar

[9]Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005Piccart-GebhartMJProcterMLeyland-JonesBet alTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med35316591672200510.1056/NEJMoa052306Search in Google Scholar

[10]Smith I, Procter M, Gelber RD, et al: 2-Year followup of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 369:29-36, 2007SmithIProcterMGelberRDet al2-Year followup of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trialLancet3692936200710.1016/S0140-6736(07)60028-2Search in Google Scholar

[11]Hudis CA: Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.HudisCATrastuzumab—mechanism of action and use in clinical practiceN Engl J Med2007357395110.1056/NEJMra04318617611206Search in Google Scholar

[12]Yavas O, Yazici M, Eren O, Oyan B: The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly 2007, 137:556-558.YavasOYaziciMErenOOyanBThe acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patientsSwiss Med Wkly200713755655810.4414/smw.2007.11899Search in Google Scholar

[13]Tsang W, Moe G. Trastuzumab and heart failure. Cardiol Rounds. 2007;8:1-6.TsangWMoeG.Trastuzumab and heart failureCardiol Rounds2007816Search in Google Scholar

[14]Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a metaanalysis of published randomized trials. BMC Cancer 2007, 7:153.VianiGAAfonsoSLStefanoEJDe FendiLISoaresFVAdjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a metaanalysis of published randomized trialsBMC Cancer2007715310.1186/1471-2407-7-153195923617686164Search in Google Scholar

[15]Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783.SlamonDJLeyland-JonesBShakSet al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med200134478310.1056/NEJM20010315344110111248153Search in Google Scholar

[16]Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215.SeidmanAHudisCPierriMKet al.Cardiac dysfunction in the trastuzumab clinical trials experienceJ Clin Oncol200220121510.1200/JCO.2002.20.5.121511870163Search in Google Scholar

[17]Wysocki PJ, Hutka M: Cardiotoxicity of 5-fluorouracil in a young colorectal cancer patient - case report and review of literature. Arch Med Sci 2009, 5:277-280.WysockiPJHutkaMCardiotoxicity of 5-fluorouracil in a young colorectal cancer patient - case report and review of literatureArch Med Sci20095277280Search in Google Scholar

[18]McKeage K, Perry CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002, 62:209-243.McKeageKPerryCMTrastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2Drugs20026220924310.2165/00003495-200262010-0000811790161Search in Google Scholar

[19]Suter TM, Procter M, Van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial. J Clin Oncol 2007, 25:3859-3865.SuterTMProcterMVan VeldhuisenDJMuschollMBerghJCarlomagnoCet alTrastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant TrialJ Clin Oncol2007253859386510.1200/JCO.2006.09.161117646669Search in Google Scholar

[20]Telli M, et al: Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. JCO 2007, 25(23):3525-3533.TelliMet alTrastuzumab-related cardiotoxicity: calling into question the concept of reversibilityJCO200725233525353310.1200/JCO.2007.11.010617687157Search in Google Scholar

[21]Meryem Aitelhaj, Siham LKhouyaali, Ghizlane Rais, Amina Mohtaram, et al: Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients. BMC Research Notes 2013, 6:339MeryemAitelhajSihamLKhouyaaliGhizlaneRaisAminaMohtaramet alCardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patientsBMC Research Notes2013633910.1186/1756-0500-6-339376576423985308Search in Google Scholar

[22]Slamon D, Eiermann W, Robert N: 006 oboB BCIRG 006:2nd interim analysis chase III randomised trial comparing doxorubicine and cyclophosphamide followed by docetaxel (AC/T) with doxorubicine and cyclo phosphamid followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. In Proceedings of San Antonio breast cancer symposium (SABCS). San Antonio: Breast Cancer Research and Treatment; 2006.SlamonDEiermannWRobertN006 oboB BCIRG 006:2nd interim analysis chase III randomised trial comparing doxorubicine and cyclophosphamide followed by docetaxel (AC/T) with doxorubicine and cyclo phosphamid followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. In Proceedings of San Antonio breast cancer symposium (SABCS)San AntonioBreast Cancer Research and Treatment2006Search in Google Scholar

[23]McArthur HL, Chia S: Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007, 357:94-95.McArthurHLChiaSCardiotoxicity of trastuzumab in clinical practiceN Engl J Med2007357949510.1056/NEJMc07006517611218Search in Google Scholar

[24]Montemurro F, Redana S, Valabrega G, Martinello R, Aglietta M, Almiero R: Trastuzumab-related cardiotoxicity in the herceptin dyuvant trial.J Clin Oncol 2008, 26:2052-2053.MontemurroFRedanaSValabregaGMartinelloRAgliettaMAlmieroRTrastuzumab-related cardiotoxicity in the herceptin dyuvant trialJ Clin Oncol2008262052205310.1200/JCO.2007.15.504418421060Search in Google Scholar

[25]Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-over - expressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.Tan-ChiuEYothersGRomondEet alAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-over - expressing breast cancer: NSABP B-31J Clin Oncol2005237811781910.1200/JCO.2005.02.4091Search in Google Scholar

[26]Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.EwerMSVooletichMTDurandJBet alReversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatmentJ Clin Oncol2005237820782610.1200/JCO.2005.13.300Search in Google Scholar

[27]Wadhwa D, Fallah-Rad N, Grenier D, et al: Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009, 117:357-364.WadhwaDFallah-RadNGrenierDet alTrastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective studyBreast Cancer Res Treat200911735736410.1007/s10549-008-0260-6Search in Google Scholar

[28]Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK: Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 2008, 83:197-203.SenguptaPPNorthfeltDWGentileFZamoranoJLKhandheriaBKTrastuzumab-induced cardiotoxicity: heart failure at the crossroadsMayo Clin Proc20088319720310.1016/S0025-6196(11)60840-9Search in Google Scholar

[29]Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J: The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010, 61:157-165.GlubaAPietruchaTBanachMPiotrowskiGRyszJThe role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot studyAngiology20106115716510.1177/000331970935125819939821Search in Google Scholar

[30]Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the NorthCentral Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.PerezEASumanVJDavidsonNEet alCardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the NorthCentral Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol2008261231123810.1200/JCO.2007.13.5467404896018250349Search in Google Scholar

[31]Pentassuglia L, Graf M, Lane H, et al: Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 2009, 315:1302-1312.PentassugliaLGrafMLaneHet alInhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytesExp Cell Res20093151302131210.1016/j.yexcr.2009.02.001499136219331811Search in Google Scholar

[32]Bowles A: Risk of heart failure in breast cancer patients after anthracyclines and Trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012, 104:1293-1305.BowlesARisk of heart failure in breast cancer patients after anthracyclines and Trastuzumab treatment: a retrospective cohort studyJ Natl Cancer Inst20121041293130510.1093/jnci/djs317343339222949432Search in Google Scholar

[33]Tocchetti C., Ragone G., Coppola C, et al: Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail 2012,14: 130-137.TocchettiC.RagoneG.CoppolaCet alDetection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challengeEur J Heart Fail20121413013710.1093/eurjhf/hfr16522219501Search in Google Scholar

[34]Braden A., Stankowski R., Engel J., et al: Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des 25 November 2013 (Epub ahead of print).BradenA.StankowskiR.EngelJ.et alBreast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrenceCurr Pharm Des25 November 2013(Epub ahead of print)10.2174/138161281966613112514551724283956Search in Google Scholar